Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Lymphoma, Non-Hodgkin 8Neoplasm Metastasis 6Breast Neoplasms 5Neoplasms 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Non-Small-Cell Lung 2Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1

Interventions

Magnetic Resonance Spectroscopy 5Iodine-131 3Fluorodeoxyglucose F18 3trametinib 2pazopanib 2belinostat 2Vemurafenib 2Trastuzumab 2Specimen Handling 2Sirolimus 2Paclitaxel 2Fluorouracil 2FAPI-46 2Docetaxel 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Biopsy 2Bevacizumab 2Azacitidine 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1romidepsin 1pembrolizumab 1naporafenib 1mercaptoundecahydrododecaborate 1fludarabine phosphate 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Thyroid Neoplasms × copanlisib × Clear all
NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
8 enrolled 8 charts
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡